This content is for informational purposes only and is not a substitute for professional advice.
Resveratrol and pterostilbene are related stilbene polyphenols, not proven longevity drugs, and neither should be framed as a treatment or prevention tool for aging, cancer, heart disease, dementia, or any other diagnosis. Start with Understanding Supplement Categories before treating either molecule as more than a cautious, time-limited supplement experiment.
Quick decision table
| Decision point | Resveratrol | Pterostilbene |
|---|---|---|
| Best fit | User wants the better-known, more studied stilbene and accepts poor bioavailability | User wants to test a more lipophilic resveratrol analog with higher exposure signals and less human outcome data |
| Typical adult supplement range | Often 100-500 mg daily; trials range much wider | Often 50-250 mg daily; human pterostilbene trials commonly used 50-125 mg twice daily |
| Evidence shape | Large preclinical literature, many human trials in selected populations, inconsistent outcome translation | Smaller human literature, stronger bioavailability rationale, limited outcome evidence |
| Main bioavailability point | Rapid metabolism and low free resveratrol exposure after oral dosing | More lipophilic and generally more orally available in animal and preclinical pharmacokinetic work |
| Main safety watch | GI effects at higher doses, bleeding caution, drug-metabolism uncertainty, hormone-sensitive contexts | LDL cholesterol increase signal in one human trial, blood-pressure and medication caution, limited long-term safety data |
| Better first pick | If the goal is to test the more researched compound at a modest dose | If bioavailability is the main hypothesis and baseline lipids are known |
| Claim to distrust | "Anti-aging proven" | "Better than resveratrol for longevity" |
The practical answer is not that pterostilbene is "upgraded resveratrol." The practical answer is that pterostilbene may produce higher exposure at lower milligram doses, and that higher exposure can raise both the chance of a signal and the need for safety monitoring.
What these molecules are
Resveratrol is a polyphenol found in grapes, wine, peanuts, berries, and Japanese knotweed extracts. Supplement labels often specify trans-resveratrol, the isomer usually discussed in research and marketing. Pterostilbene is a dimethylated analog of resveratrol found in small amounts in blueberries, grapes, and some tree species. The two molecules are close enough to invite comparison, yet they are not interchangeable.
The two added methoxy groups on pterostilbene make it more lipophilic. That chemistry is the reason pterostilbene is often described as more bioavailable. It does not prove superior health outcomes. A compound can be better absorbed and still fail to improve a chosen endpoint, worsen an unwanted marker, or be unnecessary for the person testing it. ptero-review
The marketing boundary matters. Resveratrol became famous through sirtuin, red wine, and lifespan stories that mostly came from cells, yeast, worms, flies, and rodents. Human supplement use has not established either compound as an anti-aging therapy. For healthy adults, the fair question is narrower: does a measured, single-compound trial improve a specific marker or symptom without introducing safety costs?
Evidence differences
Resveratrol has the larger research footprint. Human studies have tested it across metabolic, vascular, cognitive, inflammatory, and menopause-related contexts, often with mixed results and many differences in dose, formulation, population, and trial length. Memorial Sloan Kettering summarizes the field as promising in places and inconsistent in others, and notes that life-span effects seen in yeast have not been demonstrated in humans. msk
The biggest resveratrol translation problem is pharmacokinetics. Oral resveratrol is absorbed, then rapidly converted into sulfate and glucuronide metabolites. Reviews of human bioavailability data repeatedly describe low free-resveratrol exposure after standard oral dosing, which is why higher doses and special formulations appear so often in trials. lpi res-bioavailability
Pterostilbene has a smaller human evidence base. A randomized, double-blind, placebo-controlled pterostilbene trial in adults with elevated cholesterol tested 50 mg twice daily, 125 mg twice daily, and 50 mg plus grape extract twice daily for 6-8 weeks. Safety markers for liver, kidney, and glucose did not show adverse signals in that short trial. ptero-safety
The paired metabolic analysis from that trial reported an LDL cholesterol increase with pterostilbene, with total cholesterol rising in parallel. That finding does not prove pterostilbene is broadly harmful, and it does mean lipid monitoring is more than a nice-to-have if someone chooses pterostilbene. ptero-metabolic
There is no strong direct human head-to-head evidence showing that resveratrol or pterostilbene is the better supplement for healthy adults. A "winner" depends on the endpoint, dose, product, baseline risk, and whether the person can monitor side effects and relevant labs.
Bioavailability differences
| Bioavailability question | Resveratrol | Pterostilbene |
|---|---|---|
| Chemical pattern | Three hydroxyl groups | One hydroxyl group and two methoxy groups |
| Expected absorption issue | Rapid phase II metabolism after oral dosing | Higher lipophilicity and slower metabolism are commonly proposed advantages |
| Human relevance | More human pharmacokinetic data, often showing low free parent compound | Less direct human pharmacokinetic data as a standalone supplement |
| Practical meaning | Higher milligram dose does not guarantee higher active tissue effect | Higher exposure does not guarantee better outcome or lower risk |
| Trial lesson | Choose a consistent form and dose, then judge a real endpoint | Know baseline lipids and avoid assuming "more bioavailable" means safer |
Bioavailability is a tool variable, not a health outcome. For resveratrol, low parent-compound exposure may partly explain why strong cell or animal claims often fade in human trials. For pterostilbene, better exposure is a plausible reason to test lower doses, not a reason to skip safety review.
The correct comparison is not "which molecule survives digestion." It is "which molecule creates a measurable benefit in this person at this dose, with acceptable adverse-effect and lab tradeoffs."
Dose and timing comparison
| Use case | Resveratrol approach | Pterostilbene approach |
|---|---|---|
| First exposure | 100-150 mg with food in the morning | 50 mg with food in the morning |
| Standard self-test | 150-500 mg daily for 4-8 weeks | 50-100 mg daily for 4-8 weeks |
| Higher-dose research context | Some trials use 1,000 mg daily or more under study conditions | Human trials have used 50-125 mg twice daily for 6-8 weeks |
| GI-sensitive users | Start low and take with food | Start low and take with food |
| Sleep-sensitive users | Avoid late-day first doses | Avoid late-day first doses |
| Lipid monitoring | Useful if risk is high or trial lasts longer | Strongly preferred before and after the trial |
Morning with food is the conservative default. It reduces nausea risk and makes sleep effects easier to identify. A first dose belongs on a normal day, not before surgery, travel, a race, a major presentation, alcohol intake, or a medication change.
Do not start either compound at the same time as NMN, NR, quercetin, fisetin, curcumin, berberine, high-dose omega-3, aspirin, or a new fasting protocol. Those combinations make attribution weak and can stack interaction questions.
Safety and interactions
| Safety question | Resveratrol | Pterostilbene |
|---|---|---|
| Bleeding | In vitro antiplatelet activity and clinical caution with blood thinners; avoid casual use with anticoagulants or antiplatelet drugs | Less direct human interaction evidence; use the same caution because it is a related stilbene with limited medication data |
| Drug metabolism | Resveratrol can affect CYP enzymes and transporters in experimental and some human contexts, including CYP3A4 discussion in clinical pharmacology reviews | Less mapped in humans; caution is stronger when a medication has a narrow therapeutic window |
| Lipids | Not the main concern in most reviews, though results vary by population and dose | LDL cholesterol increase signal in a short human trial makes baseline and follow-up lipids important |
| GI effects | Nausea, gas, abdominal pain, and diarrhea are more likely at higher doses | GI effects are possible; human data are thinner |
| Pregnancy and breastfeeding | Avoid supplements unless clinician-directed; lactation safety data are insufficient | Avoid supplements unless clinician-directed; evidence is even thinner |
| Surgery | Stop ahead of surgery unless the surgical team gives different instructions because bleeding and medication questions matter | Stop ahead of surgery unless the surgical team gives different instructions |
Anyone taking warfarin, apixaban, rivaroxaban, dabigatran, clopidogrel, aspirin for cardiovascular protection, NSAIDs at meaningful frequency, chemotherapy, immunosuppressants, anticonvulsants, psychiatric medications, diabetes medications, blood-pressure medications, hormone therapies, or drugs with narrow therapeutic windows should get pharmacist or clinician review first. NCCIH's general medication-supplement guidance is the right default: supplements can increase, decrease, or otherwise change medication effects. nccih-interactions
Resveratrol deserves extra caution in hormone-sensitive medical contexts because it has estrogenic and anti-estrogenic activity in experimental systems, and Linus Pauling Institute advises avoidance of resveratrol supplements in women with a history of estrogen-sensitive cancers until more is known. This is a safety boundary, not a claim that resveratrol causes or treats those conditions. lpi
Pterostilbene deserves extra caution when LDL cholesterol is high, untreated, familial, or already difficult to manage. If a user is not willing to check lipids, pterostilbene is a poor first experiment.
Who should avoid either option
| Person or context | Resveratrol | Pterostilbene |
|---|---|---|
| Pregnant, trying to conceive, or breastfeeding | Avoid unless clinician-directed | Avoid unless clinician-directed |
| Surgery or dental procedure planned | Avoid unless surgical team approves; disclose use | Avoid unless surgical team approves; disclose use |
| Uses anticoagulant or antiplatelet medication | Avoid unsupervised use | Avoid unsupervised use |
| Easy bruising, bleeding disorder, or prior bleeding event | Avoid unless clinician-directed | Avoid unless clinician-directed |
| Complex medication list | Pharmacist review first | Pharmacist review first |
| Hormone-sensitive medical history | Avoid unless clinician-directed | Use only with clinician guidance |
| High LDL cholesterol or familial lipid risk | Use only with lab monitoring | Poor first pick unless lipids are monitored |
| Wants a proven anti-aging supplement | Wrong category | Wrong category |
| Cannot buy a lot-tested product | Avoid | Avoid |
The strongest avoid signal is a weak reason for use. If the person cannot name the endpoint, dose, duration, interaction check, and stop rule, neither compound is ready for the stack.
Unfair n-of-1 workflow
| Phase | Duration | What to log | Decision rule |
|---|---|---|---|
| Baseline | 14 days | Sleep duration, resting heart rate, HRV if available, training load, alcohol, caffeine, GI symptoms, bruising, medications, and target metric | Start only if the target metric is stable enough to compare |
| Product check | 1 day | Form, dose, third-party test status, lot number, cost per day, excipients, and disease-claim language | Reject unclear forms, proprietary blends, and products making treatment claims |
| First trial | 4-8 weeks | One molecule only, same dose time, same meal pattern, no new polyphenol stack additions | Continue only if the target metric improves without GI, sleep, bleeding, mood, or lab cost |
| Washout | 2 weeks | Same tracking without the molecule | If the benefit does not fade, confidence in the supplement drops |
| Crossover | 4-8 weeks | Test the other molecule only if the first trial was tolerated and still worth comparing | Keep the lower-risk option only if it beats baseline and washout |
| Review | 1 day | Average target metric, side effects, cost, adherence, bruising, blood pressure if available, and lipids if testing pterostilbene | Keep one, keep neither, or retest at a lower dose |
Choose one primary endpoint before the first capsule. Reasonable endpoints include a repeatable recovery metric, a clinician-approved lipid follow-up, subjective energy stability, GI tolerability, or a preselected inflammatory marker if already being checked for another reason. Poor endpoints include "anti-aging," "longevity," "cellular youth," or a single day of feeling unusually optimistic.
In Unfair, tag the trial as `polyphenol`, log resveratrol and pterostilbene as separate ingredients, and record timing relative to meals, caffeine, alcohol, exercise, and medications. Add a stop rule before starting: stop for new unusual bruising, nosebleeds, black stools, persistent diarrhea, new palpitations, rash, insomnia lasting more than three nights, or any symptom that feels meaningfully outside baseline.
Bottom line
Resveratrol is the better-known compound with broader human study history and a major bioavailability problem. Pterostilbene is the more bioavailability-forward analog with less human outcome evidence and a real lipid-monitoring caution. Neither earns longevity, cancer, heart disease, or dementia claims.
For most healthy adults, these are late-stage experiments after sleep, training, nutrition, alcohol, medication review, and higher-confidence supplements are already handled. If either enters the stack, make it boring: one molecule, modest dose, short trial, clear endpoint, interaction review, and a written stop rule.
References
This article is for education only and does not substitute for professional medical advice. Consult your clinician or pharmacist before making changes to your supplement routine.
Memorial Sloan Kettering Cancer Center. Resveratrol. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/resveratrol
↩Linus Pauling Institute, Oregon State University. Resveratrol. https://lpi.oregonstate.edu/mic/dietary-factors/phytochemicals/resveratrol
↩Smoliga JM, Blanchard O. Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution? Molecules. 2014;19(11):17154-17172. https://pmc.ncbi.nlm.nih.gov/articles/PMC6270951/
↩Riche DM, McEwen CL, Riche KD, et al. Analysis of safety from a human clinical trial with pterostilbene. J Toxicol. 2013;2013:463595. https://pmc.ncbi.nlm.nih.gov/articles/PMC3575612/
↩Riche DM, Riche KD, Blackshear CT, et al. Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial. Evid Based Complement Alternat Med. 2014;2014:459165. https://pmc.ncbi.nlm.nih.gov/articles/PMC4099343/
↩Liu Y, You Y, Lu J, et al. Recent advances in synthesis, bioactivity, and pharmacokinetics of pterostilbene, an important analog of resveratrol. Molecules. 2020;25(21):5166. https://pmc.ncbi.nlm.nih.gov/articles/PMC7664215/
↩National Center for Complementary and Integrative Health. Know the Science: How Medications and Supplements Can Interact. https://www.nccih.nih.gov/health/know-science/how-medications-and-supplements-can-interact/introduction
↩National Library of Medicine. Resveratrol. Drugs and Lactation Database. https://www.ncbi.nlm.nih.gov/sites/books/NBK501879/
↩Detampel P, Beck M, Krahenbuhl S, Huwyler J. Drug interaction potential of resveratrol. Drug Metab Rev. 2012;44(3):253-265. https://pubmed.ncbi.nlm.nih.gov/22788578/
↩